



## A Review on Artificial Intelligence in Drug Discovery : Current Application And Future Opportunities

Shivendra yadav<sup>1\*</sup>, Vishal Rai<sup>2</sup>, Shekhar Singh<sup>3</sup>

<sup>1,2,3</sup>Suyash Institute of Pharmacy, Hakkabad, Gorakhpur, Uttar Pradesh, India

### OPEN ACCESS

#### Corresponding Author

Shivendra yadav

Suyash Institute of Pharmacy,  
Hakkabad, Gorakhpur, Uttar  
Pradesh, India.

Received: 15-09-2024

Accepted: 24-10-2024

Available online: 25-11-2024



©Copyright: IJMPS Journal

### ABSTRACT

Drug discovery stands at the heart of developing new therapies; that is the engine behind the medical science in developing new and healthy approaches to save life. As such, the pharmaceutical industry needed rapid responses during the COVID-19 pandemic, so AI was called for finding potential drug candidates. The pharmaceutical industry changes in crises since AI lowers the time and the cost significantly in discovering drugs. Vast data, whether big or small, are efficiently analyzed and processed by AI so that drug candidates are optimized, and drug-target interactions can be predicted, thus shortening the timeline of discovering new treatments.

Rapid advancement of AI technology in drug discovery presents significant challenges for regulatory bodies to maintain safety and efficacy profiles of new treatments. And despite AI's great stride, it still has obstacles in the field. Data integrity and regulatory frameworks are important, as well as the ethical concerns associated with them. The trend of essential integration of AI into drug discovery is sure to emerge given the current evolution of technology, providing the potential for more personalized and effective treatments that can address both current and future health care demands.

**Key Words:** Drug Discovery, Drug Target Interaction, Lead compound, Optimizations.

### Introduction :

#### Artificial Intelligence

Computer systems can perform a many tasks requiring human intelligence, such as learning, problem-solving, and language understanding, through Artificial Intelligence (AI). [1]

AI is used in the discovery and development of drug, to speed up the process, to decrease th cost, and enhance accuracy in identifying the potential drugs. This is achieved as follows:

- 1. Identifying Drug Candidates:** Endless datasets of chemical compounds can be analyzed by AI-powered calculations to foresee which one will connected successfully with natural targets, subsequently essentially speeding up the distinguishing proof of unused sedate candidate.
- 2. Predicting Drug-Target Interactions:** By analyzing biochemical data through machine learning models. This makes it possible to predict how new pharmaceutical compounds will interact with disease targets. Eliminates the need for expensive and time-consuming laboratory experiments.
- 3. Optimization of drug designing with AI:** It allows an optimization of the molecule of pharmaceutical compounds that concentrate upon efficacy, bioavailability and safety.
- 4. Speeding Up Clinical Trials:** AI evaluates medical records and predicts response to treatment for patient recruitment.
- 5. Repurposing Existing Drugs:** Since AI systems can be applied in the investigation of any drugs, such systems may, therefore allow the discovery of new therapeutic applications. It will reduce the time taken before treatments come to the market. [2]

#### 1- Importances of AI in Drug Discovery

The process of drug discovery develops new treatments which play a crucial role in medical science and improves the health outcome and saves a lot of lives. From common ailments to rare diseases, this intricate multi-stage process addresses emerging and existing health threats. A number of aspects point out the importance of drug discovery: public health improvements, advancement in scientific knowledge, and filling up unmet medical needs.

### **1.1 Addressing Unmet Medical Needs**

Many diseases, ranging from the rarest of illnesses to cancers and viral infections, have no effective treatment. It is here that new discoveries are found in drug discovery. Some of these are: Diseases like Alzheimer's, ALS, and various cancers have no cure to date. The drugs are just symptomatically palliative. These unmet needs are addressed through advancements in drug discovery, which identify new therapeutic targets and develop more effective, specialized treatments [3]. For example, the discovery of new cancer immunotherapies has revolutionized the treatment of certain cancers, providing options for patients who previously did not respond to conventional chemotherapy [4].

### **1.2 Improving Public Health and Longevity**

Drug discovery directly impacts the improvement of public health through medication delivery that decreases mortality rates, controls chronic diseases, and stops disease progression. The discovery of antibiotics, vaccines, and antiviral drugs has significantly reduced deaths from infectious diseases. One of the greatest successes is the advent of ART for HIV/AIDS, changing the disease from fatal to manageable [5].

Similarly, the development and widespread application of statins to manage cholesterol have drastically reduced deaths from cardiovascular disease, which is among the world's leading causes of death [6]. Such advances in drug discovery are directly linked to extended lifespans and quality life for millions.

### **1.3 Economic and Social Impact**

The pharmaceutical industry has an enormous economic impact worldwide. Drug discovery is highly reliant on the pharmaceutical industry, and new drugs improve both patient outcomes and cut healthcare costs through better treatments, shorter stays in hospitals, and fewer invasive procedures that require longer periods of hospital stay [7].

Other points, the invention of new drugs brings up economic growth in research, production, and testing. Moreover, diseases such as diabetes, hypertension, and mental health disorders are very expensive conditions to the economy; new treatments for the same reduce indirect costs like lost productivity and extended disablement care [8].

### **1.4 Responding to Emerging Health Threats**

The rapid drug discovery and development efforts during the COVID-19 pandemic were highly urgent and emphasized the necessity for prompt action in a health crisis. Effective antiviral drugs, like Remdesivir, and vaccines developed within one year of the virus discovery helped in managing the health emergency at the global level [9].

Such momentums generated, due to advances in computational biology and AI working synergistically hand-in-hand through collaborative globalization involving pharmaceutical industries as well as institutions of learning. So much as to put up with role the discovery and innovation, therefore is against pandemics for ensuring preparatory input from all bases, on what forms that unexpecting global tempest without an apriority notice.

### **1.5 Advancing Scientific Knowledge**

Drug discovery is not only focusing on finding cures for diseases but also advancing scientific knowledge about diseases, human biology, and the mechanisms with which drugs interact with bodies. Often, a drug discovery will reveal new aspects of molecular biology, biochemistry, and physiology on which future innovations can rest.

For example, the identification of kinase inhibitors for a cancer drug such as imatinib contributed to enhancing our knowledge on cell signalling pathways and their interaction with cancer [10]. Up to date, such knowledge supports the development of more therapies and the use of precision medicine, whereby the treatment regime is tailored to each patient according to his or her genetic profile, environmental exposure, and life habits [11].

### **1.6 Enhancing Global Health Equity**

Drug discovery is crucial to meeting this challenge because it could provide treatments for diseases that disproportionately burden low- and middle-income countries. Malaria, tuberculosis, and NTDs are diseases that have traditionally been underfunded in drug development because they have low profit prospects for pharmaceutical companies. Global health initiatives and partnerships, led by organizations like the World Health Organization (WHO) and the Bill and Melinda Gates Foundation, have increased investments into discovering and delivering treatments for these diseases [12].

But their efforts would help make life-saving medications available to some of the world's most vulnerable populations, reducing global disease burden and promoting health equity across the world.

## **2. Applications of AI in Drug Discovery**

This is how AI is infused into drug discovery as a means to revolutionize traditional drug development processes. AI can track vast biological and chemical datasets, deduce molecular behaviors, and optimize drug candidates much more effectively, hence greatly decreasing the often-considerable time and cost involved in drug development.

### **2.1 Target Identification and Validation**

Target identification is the first important step in drug discovery. AI helps in predicting potential biological targets by processing large datasets to identify disease-related genes, proteins, or pathways that can be modulated by therapeutic agents. This approach significantly increases the speed and accuracy of target identification compared with traditional methods.

Machine learning techniques such as Random Forest, SVMs, and neural networks are currently utilized to analyze large-scale omics data. This gives researchers a better, bias-free pinpointing of validation of disease targets.

Example of AI use: AlphaFold is such a significant development by DeepMind that has revolutionized the field of protein structure prediction. Understanding the process of protein folding is very vital for understanding biological processes, including designing drugs targeting proteins. AlphaFold for the first time reached extraordinary accuracy in

predicting 3D structures of proteins which solved one of the more difficult problems in biology [13]. This will therefore enable scientists to better understand how drugs interact with their targets, hence enhancing their strategies in drug design [14].

## **2.2 Lead Compound Identification**

Once the biological target has been identified, lead compounds are selected that are defined here as chemical entities capable of binding to the target and modulating its function in a therapeutic manner. AI is used to filter through the millions of compounds in a library to pick out the compounds with the greatest probability of effective binding to the target.

The most relevant AI techniques here are Generative Adversarial Networks (GANs), and Recurrent Neural Networks (RNNs). For example, GANs comprise two neural networks: one generating new compounds and the other evaluating these compounds iteratively, with refinement towards the promising candidates [15].

Example: AI-powered molecular design platforms can design novel chemical structures with desirable pharmacokinetic properties. For example, BenevolentAI uses machine learning to analyze large datasets and discover biological targets, leading to the generation of new chemical compounds with optimal drug-like properties. This AI-driven process accelerates the identification of new drug leads [16].

## **2.3 Lead Compound Optimization**

Often after the discovery of a lead compound, optimization is required to improve its therapeutic properties, such as potency, selectivity, and safety. AI aids in this respect by predicting how changes in the chemical structure of a compound would impact its interaction with the biological target.

The AI-fueled QSAR models are now increasingly being used to predict the biological activity of molecules from their chemical structure. It has enabled researchers to simulate thousands of structural modifications and their effects on the potency and safety of the compound before laboratory experiments [17].

Example: Companies such as Exscientia use AI-based platforms to optimize lead compounds by modeling the structure-activity relationship. Their AI systems can design and evaluate thousands of compounds in silico, thus significantly reducing the need for extensive laboratory experimentation [18].

## **2.4 AI in Drug-Drug Interactions and Safety Evaluation**

Drug discovery involves much safety assessment in drugs. AI predicts drug-drug interactions (DDIs) and potential adverse drug reactions (ADRs) through an analysis of large data sets that include patient data, drug chemical properties, and known interactions.

Predictive algorithms, especially deep learning models, predict how a new drug might interact with other drugs in the body or cause unexpected side effects. This is critical for improving the safety profiles of drugs before they are sent into clinical testing.

Example: IBM Watson AI platforms help in safety studies by analyzing medical records and genetic data along with biochemical databases for adverse reactions and hence enhancing risk review in the preclinical study [19].


## **2.5 AI in Clinical Trials**

All these are now reformed through AI to optimize patient recruitment for clinical trials, streamline their protocols, and predict the outcomes of their results.

NLP is applied as a subset of AI and used to extract valuable insights in clinical trial reports, medical records, and scientific literature. AI also helps in designing adaptive clinical trials; treatment protocols are adjusted by real-time patient responses, so the efficacy of the clinical trial increases.

Example: AI can scan patient data so that it picks the most suitable candidates who are likely to respond to the treatment. That way, the chance of trial failure, commonly resulting from the variability of patients, is reduced [20].

## AI Applications in Drug Discovery



### 3. Case Studies of AI in Drug Discovery

#### 3.1 AI in the Fight Against COVID-19


The COVID-19 pandemic called for quick responses from the pharmaceutical industry, and artificial intelligence (AI) became a crucial tool in identifying and developing drug candidates. AI technologies enabled researchers to scan large datasets and identify existing medications that could be repurposed to fight SARS-CoV-2, the virus responsible for COVID-19.

For instance, the drugs company BenevolentAI used AI algorithms to screen millions of already existing drugs in a 10,000-compounds database and identified Baricitinib, an approved arthritis drug, as holding promise for COVID-19. Further, this discovery helped put the drug into emergency-use authorization by the U.S. Food and Drug Administration late in November 2020. This is one example whereby AI accelerates drug repositioning efforts [21].

Apart from that, the researchers from MIT designed AI models which, by analyzing the structure of the virus and its interactions with human cells, helped to predict potential therapies for COVID-19. Their efforts provided an opportunity for prioritizing compounds for further testing. In this context, it can be noted that AI helps in streamlining drug discovery during emergencies in healthcare [22].

It meant the potential of AI in drastically shortening the time to find a drug, an essential development during times of crisis and with the future direction it was taking in its overall approach.

AI in COVID-19 Drug Discovery



#### 3.2 Insilico Medicine and Deep Learning in Oncology Drug Development

Insilico Medicine is a leader in artificial intelligence-based drug discovery, using deep learning techniques to enhance the screening rate of novel candidates, especially in oncology. Their platform is proprietary, and it combines GANs with reinforcement learning to further optimize molecular structures for rapid acceleration of the drug discovery process.

In a remarkable achievement, Insilico Medicine reported the discovery of a new compound for the treatment of fibrosis within just 46 days—a task that typically demands years of research and development. The compound, designated

ISM001-055, was identified through the company's AI platform, which simulated the chemical properties of potential drugs and forecasted their biological activities. Subsequent preclinical studies indicated that ISM001-055 demonstrated promising efficacy, underscoring the effectiveness of AI in identifying viable therapeutic candidates.[23]

This breakthrough underlines the tremendous potential of AI technologies in oncology, as most drug discovery methods have long been protracted and expensive. Insilico Medicine's success exemplifies how AI can streamline the development pipeline to bring more rapid and efficient treatment options to patients.[24]

#### 4. Obstacles and Challenges to AI in Drug Discovery

The use of Artificial Intelligence in drug discovery brings forth many benefits, including shorter timelines and reduced costs. However, there are various challenges and limitations that have to be addressed in order to fully realize the potential of AI in this field. This section discusses two major challenges: data quality and availability, and regulatory obstacles.

##### 4.1 Data quality and availability

###### 4.1.1 Incomplete and Noisy Data

One of the critical difficulties in AI-driven drug discovery is data quality as presented to training machine learning algorithms. Data sets, which are widespread in the pharmaceuticals sector, are full of problems linked to incompleteness, inconsistency, and noise. Incompleteness occurs due to different factors: missing entries, unrecorded outcome data, or under-representative coverage of varied populations of patients. The weaknesses could highly degrade the capacity for AI to train such models with an effective approach leading to biased predictions of candidates.

Additionally, noisy data, which includes errors or irrelevant information, can hide meaningful patterns on which AI models rely to make accurate predictions. For instance, data from laboratories or clinical trials may be of variable quality and standards of measurement, which makes it hard to train AI algorithms [25]. In the absence of high-quality data, false positives or negatives may occur with increased likelihood, which might result in failures at the later stages of drug development.

###### 4.1.2 Proprietary Nature of Pharmaceutical Data

The proprietary nature of the pharmaceutical data is another major challenge facing the advancement of AI tools in drug discovery. Most pharmaceutical companies are reluctant to share their datasets on intellectual property, competitive advantage, or for confidentiality reasons. This hesitation towards the sharing of the datasets constrains the researchers and developers of AI models in developing open-access models that could enhance collaboration and innovation in drug discovery [26].


Easing this problem is to build standardized frameworks for the collaborative or shared exchange of information along with open platforms as developing high-quality datasets makes them accessible, while private or proprietary information remains secret and protected. For instance, another example for collaborative or diverse and inclusive database-making endeavors is that of All of Us Research Program of Research [27].

##### 4.2 Regulatory Barriers

###### 4.2.1 Inadequate Regulatory Frameworks

The fast pace of accelerating AI technologies within drug discovery appears to pose immense challenges to the regulatory agencies responsible for the review of safety and efficacy of new drugs and treatments. The current legal frameworks in places like the U.S. Food and Drug Administration are still very under-equipped when dealing with the complexities of AI-driven tools and their applications[28]. This will change the traditional regulation processes, which mainly are based on established procedures, hardly taking into consideration that it has an adaptive nature to machine learning models because it develops and improves as there is increasing exposure to new data.

The danger lies in setting up proper guidelines that can sufficiently evaluate the reliability, reproducibility, and accountability of AI systems throughout the entire drug development process. Regulatory bodies are more aware of such lacunas and are working critically to set up new frameworks for AI technologies. The FDA is planning a Digital Health Innovation Action Plan in the promotion of innovation while making sure that AI-driven tools meet safety and efficacy standards[29].



#### 4.2.2 Ethical Considerations and Transparency

The second critical regulatory issue involves ethical considerations in drug discovery by the use of AI. Matters such as data privacy, informed consent, and bias in algorithms are key areas to be addressed in the applications of AI, making them ethically sound [30]. The regulation also has to emphasize transparency in the AI decision-making process. Because AI systems tend to act like "black boxes," revealing the logic by which models reach their conclusions can be an important part of achieving regulatory approval and public acceptance.

The development of transparent AI systems will require the involvement of AI researchers, ethicists, and regulatory bodies in setting standards that make interpretation possible without inhibiting innovation [31]. Ethical frameworks, such as the EU's Guidelines on Ethics in Artificial Intelligence, foster responsible AI development by highlighting accountability and transparency in AI-driven healthcare application [32].

### 5. AI Tools and Technologies in Drug Discovery

#### 5.1 Machine Learning Algorithms

Machine learning has significantly changed the face of drug discovery by allowing it to analyze vast datasets within short periods, optimize candidates, and predict drug-target interactions. These can be grouped into three categories-supervised, unsupervised, and reinforcement learning algorithms.

**Supervised Learning:** In the drug discovery process, labeled datasets train supervised learning models, so they can forecast drug properties like toxicity, efficacy, and bioavailability. As an example, the random forest algorithm is used for predicting the compounds' bioactivity based on molecular descriptors to identify prospective candidates earlier [33]. SVM algorithms have also been used in classifying compound based on biological activity [34].

**Unsupervised Learning:** It has been employed to detect hidden patterns of chemical and biological data not defined with the labels. It was utilized to classify molecules into different groups using their structural similarity, that can allow the researchers to find out possible drug candidates by structure-function relationship research [35]. For example, PCA was applied to diminish the chemical space dimension and assist in discovering new molecules with a drug-like quality [36].

**Reinforcement Learning (RL):** Reinforcement learning has recently gained popularity in the de novo design of drugs, where an agent will explore chemical space to find new molecules optimized for a particular set of properties [38]. Deep reinforcement learning combines this approach with neural networks to design more complex molecules that optimize multiple drug-like characteristics simultaneously [38].

#### 5.2 Deep Learning and Neural Networks

Deep learning is, in fact a sub-area of machine learning and comprises artificial neural networks in the modeling of complex relationships within highly dimensional datasets. It is rapidly becoming an absolute tool in drug discovery, besides predicting molecular activity, toxicity, and efficacy.

**Convolutional Neural Networks:** CNNs are applied especially on structural data like molecular graphs or protein-ligand interactions. It has also been used in virtual screening to predict the binding affinity of small molecules to a target protein [39]. CNNs have also been applied in the structure-based drug design in order to optimize compounds based on analyzing 3D structures of drug-protein complexes [40].

**Recurrent Neural Networks (RNNs):** RNNs, including the Long Short-Term Memory (LSTM) network, are particularly well-suited for sequence-based tasks, such as predicting drug responses from chemical sequences. RNNs have been used to model the temporal dynamics of drug interactions, advancing drug repurposing efforts by analyzing historical treatment data [41,42].

**Generative Adversarial Networks:** GANs are the frontier tool in de novo drug design, meaning they create novel compound(s) with desirable properties. GANs include two kinds of neural networks: one is a generator proposing new molecules and another one is a discriminator which can differentiate between real and generated molecule. The iteration helps to develop highly optimized drug candidates [43]. GANs have well worked especially in generating compounds which satisfy multiple pharmacological criteria at the same time [44].

Another key role of deep learning is in the prediction of the ADMET properties of drugs, which means that inappropriate candidates can be ruled out as early as possible in the development process [45].

#### Conclusion:

Artificial Intelligence is changing the landscape of drug discovery. Its advantages include accelerated timelines in the development of drugs, optimization of molecular designs, and a more accurate prediction of drug-target interactions. This means that AI will therefore be able to shorten the time and cost for the discovery of new treatments using powerful machine learning algorithms, deep learning, and data-driven techniques. It contributed from the identification of novel drug candidates to optimization of their structures, safety profile, and more efficient clinical trials.

While the AI revolution drastically changes the pharmaceutical sector, numerous problems persist-most critically regarding quality, regulatory considerations, and ethics. Making AI-based drug discovery not only efficient but safe, transparent, and equitable will be necessary to address such issues. As technology continues to advance, AI is perceived to be a core component of drug discovery, aiming at painting off a personalized and effective treatment for conditions that both already exist and are emerging.

## Reference:

1. Russell, S., & Norvig, P. (2010). *Artificial Intelligence: A Modern Approach* (3rd ed.). Prentice Hall.
2. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. *Drug Discovery Today*, 24(3), 773-780.
3. Scannell, J. W., et al. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. *Nature Reviews Drug Discovery*, 11(3), 191-200.
4. Couzin-Frankel, J. (2013). Cancer immunotherapy. *Science*, 342(6165), 1432-1433.
5. Palella, F. J., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *New England Journal of Medicine*, 338(13), 853-860.
6. Stone, N. J., et al. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. *Journal of the American College of Cardiology*, 63(25), 2889-2934.
7. DiMasi, J. A., et al. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of Health Economics*, 47, 20-33.
8. OECD. (2021). The economic burden of diabetes and hypertension: Implications for public policies. *OECD Health Working Papers*.
9. Beigel, J. H., et al. (2020). Remdesivir for the treatment of Covid-19 — final report. *New England Journal of Medicine*, 383(19), 1813-1826.
10. Druker, B. J., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *New England Journal of Medicine*, 344(14), 1031-1037.
11. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372(9), 793-795.
12. Hotez, P. J., et al. (2007). Control of neglected tropical diseases. *New England Journal of Medicine*, 357(10), 1018-1027.
13. Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596, 583–589. DOI: [10.1038/s41586-021-03819-2](https://doi.org/10.1038/s41586-021-03819-2)
14. Senior, A. W., Evans, R., Jumper, J., et al. (2020). Improved protein structure prediction using potentials from deep learning. *Nature*, 577, 706-710. DOI: [10.1038/s41586-019-1923-7](https://doi.org/10.1038/s41586-019-1923-7)
15. Kadurin, A., Nikolenko, S., Khrabrov, K., & Aliper, A. (2017). Drug discovery with Generative Adversarial Networks. *Molecular Pharmaceutics*, 14(9), 3098-3104. DOI: [10.1021/acs.molpharmaceut.7b00346](https://doi.org/10.1021/acs.molpharmaceut.7b00346)
16. Segler, M. H., Kogej, T., Tyrchan, C., & Waller, M. P. (2018). Generating focused molecule libraries for drug discovery with recurrent neural networks. *ACS Central Science*, 4(1), 120-131. DOI: [10.1021/acscentsci.7b00512](https://doi.org/10.1021/acscentsci.7b00512)
17. Cherkasov, A., Muratov, E. N., Fourches, D., et al. (2014). QSAR modeling: where have you been? Where are you going to? *Journal of Medicinal Chemistry*, 57(12), 4977-5010. DOI: [10.1021/jm4004285](https://doi.org/10.1021/jm4004285)
18. Hopkins, A. L., & Groom, C. R. (2002). The druggable genome. *Nature Reviews Drug Discovery*, 1(9), 727-730. DOI: [10.1038/nrd892](https://doi.org/10.1038/nrd892)
19. Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. *Computational and Structural Biotechnology Journal*, 13, 8-17. DOI: [10.1016/j.csbj.2014.11.005](https://doi.org/10.1016/j.csbj.2014.11.005)
20. Esteva, A., Kuprel, B., Novoa, R. A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature*, 542, 115–118. DOI: [10.1038/nature21056](https://doi.org/10.1038/nature21056)
21. BenevolentAI. (2020). "AI-Driven Discovery of Baricitinib as a Treatment for COVID-19." Retrieved from [BenevolentAI](#).
22. Teng, H., et al. (2020). "Deep learning in drug discovery: advances and challenges." *Nature Reviews Drug Discovery*, 19(7), 487-488. doi:10.1038/d41573-020-00134-7.
23. Insilico Medicine. (2020). "AI for Drug Discovery: Accelerating the Discovery of New Treatments." Retrieved from [Insilico Medicine](#).
24. Zhang, D., et al. (2021). "AI-Driven Drug Discovery: A Case Study of Insilico Medicine." *Frontiers in Pharmacology*, 12, 652455. doi:10.3389/fphar.2021.652455.
25. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. *Drug Discovery Today*, 24(3), 773-780. DOI: 10.1016/j.drudis.2018.11.014.
26. Walsh, S. (2020). The impact of data availability on machine learning in drug discovery. *Pharmaceutical Research*, 37(1), 1-6. DOI: 10.1007/s11095-019-02783-5.
27. National Institutes of Health. (2021). All of Us Research Program. Retrieved from
28. U.S. Food and Drug Administration. (2019). Artificial Intelligence and Machine Learning in Software as a Medical Device.

29. U.S. Food and Drug Administration. (2021). Digital Health Innovation Action Plan.
30. Jobin, A., Ienca, M., & Andorno, R. (2019). The Health Ethics & Artificial Intelligence project: Ethical challenges in the use of AI in healthcare. *BMC Medical Ethics*, 20(1), 1-13.
31. Lipton, Z. C. (2018). The mythos of model interpretability. *Communications of the ACM*, 61(10), 36-43. DOI: 10.1145/3236386.
32. European Commission. (2019). Ethics Guidelines for Trustworthy AI.
33. A. Rifaioğlu et al., "Recent applications of machine learning in drug discovery: A big data perspective," *Computational and Structural Biotechnology Journal*, vol. 17, pp. 207-218, 2019.
34. E. Vamathevan et al., "Applications of machine learning in drug discovery and development," *Nature Reviews Drug Discovery*, vol. 18, pp. 463-477, 2019.
35. A. Mamoshina et al., "Applications of deep learning in biomedicine," *Molecular Pharmaceutics*, vol. 13, no. 5, pp. 1445-1454, 2016.
36. J. Zhang et al., "Recent advances in the application of machine learning in drug discovery," *Frontiers in Molecular Biosciences*, vol. 8, p. 632047, 2021.
37. J. A. Brown et al., "Reinforcement learning for de novo drug design," *Journal of Chemical Information and Modeling*, vol. 59, no. 3, pp. 1096-1108, 2019.
38. W. Gao et al., "A generative framework for de novo molecular design with deep reinforcement learning," *ACS Central Science*, vol. 4, pp. 1417-1428, 2018.
39. T. Shaker et al., "Applications of convolutional neural networks in bioinformatics," *Current Genomics*, vol. 21, no. 4, pp. 279-287, 2020.
40. A. Jiménez-Luna et al., "Drug discovery with explainable artificial intelligence," *Nature Machine Intelligence*, vol. 2, pp. 573-584, 2020.
41. H. Hochreiter et al., "Long short-term memory," *Neural Computation*, vol. 9, no. 8, pp. 1735-1780, 1997.
42. T. Mikolov et al., "Recurrent neural networks for language modeling," *Interspeech*, pp. 1045-1049, 2010.
43. S. Kadurin et al., "The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology," *Oncotarget*, vol. 8, no. 52, pp. 108083-108090, 2017.
44. Gupta et al., "Generative models for de novo drug design," *Nature Reviews Drug Discovery*, vol. 17, pp. 97-113, 2018.